See the DrugPatentWatch profile for prolia
A biosimilar for Prolia (denosumab) is being developed by Amgen, the originator of Prolia. The development of biosimilars aims to offer more affordable treatment options for patients.
What is Prolia used for?
Prolia is a medication prescribed to treat osteoporosis in postmenopausal women and men at increased risk of fractures. It is also used to treat glucocorticoid-induced osteoporosis and to manage bone loss in men and women taking certain cancer therapies. Prolia works by decreasing the activity of osteoclasts, which are cells that break down bone [1].
When does Prolia's patent expire?
The patent exclusivity for Prolia is a key factor in the development of biosimilars. DrugPatentWatch.com tracks patent expiration dates and provides information on potential biosimilar entry [2]. Specific patent expiration dates can be complex and may involve multiple patents with varying expiration times.
Who is developing a biosimilar for Prolia?
Amgen, the company that manufactures Prolia, is also developing a biosimilar version of the drug. This is not uncommon, as originator companies often work on their own biosimilar versions to compete in the market [1].
How do biosimilars work?
Biosimilars are biological products that are highly similar to an already approved biological medicine, known as the reference product. They must demonstrate no clinically meaningful differences in terms of safety, purity, and potency. The development process for biosimilars involves rigorous analytical, non-clinical, and clinical studies to prove this similarity [3].
What is the potential impact of Prolia biosimilars?
The introduction of biosimilars for Prolia is anticipated to increase market competition. This competition often leads to lower prices for treatments, making them more accessible to a wider patient population. This can reduce healthcare costs and improve patient access to important therapies [3].